Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Glaucoma Eye, Open-angle Glaucoma, Close...
Phase Not Applicable
Enrollment 132
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Glaucoma surgery currently relies on a wide therapeutic arsenal, ranging from conventional filtering surgeries to minimally invasive glaucoma surgery (MIGS). These techniques offer distinct efficacy and safety profiles, allowing tailored management across a broad spectrum of patients. Traditionally, surgical success has been evaluated using objective clinical outcomes, such as intraocular pressure (IOP) reduction and decreased reliance on topical treatments. However, the shift toward patient-centered medicine now requires consideration of the patient's perspective, including their subjective experience and the impact of treatment on quality of life. In this context, quality-of-life assessment has become a key component, promoting therapeutic alliance and patient adherence to care pathways. Despite its importance, few studies have evaluated and compared quality of life after glaucoma surgery using comparable surgical techniques. Furthermore, to our knowledge, no study has specifically assessed the independent effect of postoperative follow-up on quality of life after filtering surgery with a bleb. Given that postoperative management can be prolonged and demanding, it may significantly influence patients' perceptions of surgical outcomes and overall well-being. This study aims to address these gaps by providing a more comprehensive evaluation of the impact of glaucoma surgery beyond traditional clinical outcomes. It may represent a first step toward the development of a more appropriate assessment tool that incorporates the realities of postoperative follow-up and the specific experiences of patients undergoing filtering surgery. The study is based on the following hypotheses: filtering glaucoma surgery preserves patients' quality of life, with a stable NEI VFQ-25 score at six months postoperatively; postoperative quality of life may be influenced by the patient's postoperative care pathway; and quality-of-life scores remain correlated with objective clinical parameters, including intraocular pressure, visual acuity, medical treatment burden, and visual field damage.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: NEI-VFQ-25 (National Eye Institute Visual Function Questionnaire-25). — The NEI-VFQ-25 questionnaire, translated into French and validated by the French National Authority for Health (HAS), is used to assess quality of life related to visual function. This questionnaire includes 25 items divided into 11 subdomains assessing vision-related functioning and 1 subdomain assessing general health status (see appendix for the detailed list). The composite score ranges from 0 to 100, with lower scores indicating a poorer perceived level of health and visual functioning.

Primary Outcomes

  • Quality of life score from the NEI-VFQ-25 (National Eye Institute Visual Function Questionnaire-25). (Pre-operative period and 6 months after intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-02-23
Completion: 2027-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 132 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospices Civils de Lyon
Contact Information
Study Contact:
Victor VERMOT-DESROCHES, MD
426109431
victor.vermot-desroches@chu-lyon.fr
Christelle SZATANEK
426732724
christelle.szatanek@chu-lyon.fr
Victor VERMOT-DESROCHES, MD
426109431
victor.vermot-desroches@chu-lyon.fr
Service d'Ophtalmologie, Hôpital de La Croix Rousse, Hospices Civils de Lyon
Interventions
  • Other: NEI-VFQ-25 (National Eye Institute Visual Function Questionnaire-25). — The NEI-VFQ-25 questionnaire, translated into French and validated by the French National Authority for Health (HAS), is used to assess quality of life related to visual function. This questionnaire includes 25 items divided into 11 subdomains assessing vision-related functioning and 1 subdomain assessing general health status (see appendix for the detailed list). The composite score ranges from 0 to 100, with lower scores indicating a poorer perceived level of health and visual functioning.
Study Locations (1 sites)
Service d'Ophtalmologie, Hôpital de La Croix Rousse, Hospices Civils de Lyon, Lyon, 69317 France
Eligibility Criteria
Inclusion Criteria: * Patient aged ≥ 18 years with an indication for glaucoma surgical treatment * Eligible surgical procedures: Preserflo™ MicroShunt with mitomycin C, Trabeculectomy with mitomycin C or non-penetrating deep sclerectomy with mitomycin C * Unilateral or bilateral glaucoma, open-angle or angle-closure, at early, moderate, or advanced stages * Pseudoxexfoliative or pigmentary glaucoma * Secondary glaucoma, including: uveitic glaucoma, Steroid-induced glaucoma, traumatic glaucoma * Written informed consent obtained prior to study participation Exclusion Criteria: * Congenital glaucoma * Refractory glaucoma with a history of multiple previous surgeries * Ophthalmologic surgery within 6 months prior to inclusion * Severe visual co-morbidities (age-related macular degeneration, severe diabetic retinopathy, retinal degeneration, or similar conditions) * Expected difficulty with follow-up including poor anticipated compliance, planned travel or prolonged absence during the follow-up period * Illiteracy, inability to speak French or impaired cognitive capacity preventing adequate understanding of the study * Patients with a significant pre-existing impairment in quality of life attributable to a progressive physical illness or a neuropsychiatric disorder. * Patients under curatorship or guardianship * Pregnant women
Conditions Diabetes Mellitus, Diabetes Mellitus, Ty...
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A prospective, multicenter evaluation of performance and safety of the Eversense Gemini System with flash glucose measurement feature. The purpose of this clinical investigation is to evaluate the accuracy of the Gemini System with new technological flash glucose monitoring (FGM) feature enhancements compared to reference glucose measurements and the Eversense 365 CGM System. The investigation will also evaluate safety of the Gemini System usage.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Device: Continuous Glucose Monitoring System — Eversense 365 Continuous Glucose Monitoring System and Gemini Glucose Monitoring System

Primary Outcomes

  • System agreement (15/15%, 20/20%, 30/30%, and 40/40%) for paired sensor FGM and reference measurements post-insertion for reference glucose values from 40-400 mg/dL. (365 days)
  • Number of device-related or sensor insertion/removal procedure-related serious adverse events (365 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-29
Completion: 2028-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Senseonics, Inc.
Contact Information
Study Contact:
Maggie Lewis
667-218-3309
maggie.lewis@senseonics.com
Susan Huynh
301-407-2923
susan.huynh@senseonics.com
Jenine Yager Stone, PhD, MSN, FNP-C
760-466-1520
jenine.yagerstone@headlandsresearchamcr.com
Headlands Research - AMCR Institute
Interventions
  • Device: Continuous Glucose Monitoring System — Eversense 365 Continuous Glucose Monitoring System and Gemini Glucose Monitoring System
Study Locations (1 sites)
Headlands Research - AMCR Institute, Escondido, California 92025 United States
Eligibility Criteria
Inclusion Criteria: Subjects meeting all of the following inclusion criteria will be included in this study: 1. Subjects ≥18 years of age 2. Clinically confirmed diagnosis of diabetes mellitus for ≥1 year 3. Subject has signed an informed consent form (ICF) and is willing to comply with protocol requirements Exclusion Criteria: Subjects meeting any of the following exclusion criteria at the time of screening will be excluded from this study: 1. History of severe hypoglycemia in the previous 6 months. Severe hypoglycemia is defined as hypoglycemia resulting in loss of consciousness or seizure. 2. History of diabetic ketoacidosis requiring emergency room visit or hospitalization in the previous 6 months. 3. Subjects with gastroparesis. 4. Female subjects of childbearing capacity (defined as of childbearing age and as not surgically sterile or not menopausal for ≥ 1 year) who are lactating or pregnant, intending to become pregnant, or not practicing birth control during the course of the study. 5. A condition preventing or complicating the placement, operation, or removal of the sensor or wearing of transmitter, including upper extremity deformities or skin condition. 6. Symptomatic coronary artery disease; unstable angina; myocardial infarction, transient ischemic attack or stroke in the past 6 months; uncontrolled hypertension (systolic\>160 mm Hg or diastolic \>100 mm Hg at time of screening); current congestive heart failure; history of cardiac arrhythmia (benign PACs and PVCs allowed). Subjects with asymptomatic coronary artery disease (e.g., CABG, stent placement or angioplasty) may participate if negative stress test within 1 year prior to screening and written clearance from Cardiologist documented. 7. Hematocrit \<38% or \>60% at screening 8. History of hepatitis B, hepatitis C, or HIV 9. Current treatment for a seizure disorder unless written clearance by neurologist to participate in study. 10. History of adrenal insufficiency 11. Currently receiving (or likely to need during the study period): immunosuppressant therapy; chemotherapy; anticoagulant/antithrombotic therapy (excluding aspirin); topical glucocorticoids over sensor site only; antibiotic for chronic infection (e.g., osteomyelitis, endocarditis) 12. A condition requiring or likely to require magnetic resonance imaging (MRI) 13. Known topical or local anesthetic allergy 14. Known allergy to glucocorticoids 15. Any condition that in the investigator's opinion would make the subject unable to complete the study or would make it not in the subject's best interest to participate in the study. Conditions include but are not limited to psychiatric conditions, known current or recent alcohol abuse or drug abuse by subject history, a condition that may increase the risk of induced hypoglycemia or risk related to repeated blood testing. Investigator will supply rationale for exclusion 16. Participation in another clinical investigation (drug or device) within 2 weeks prior to screening or intent to participate during the study period 17. The presence of any other active implanted device (as defined further in the protocol)
Conditions HER2-positive Breast Cancer
Phase PHASE3
Enrollment 540
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, multicenter, open-label, phase 3 study evaluating the efficacy, safety, and tolerability of IBI354 combined with or without pertuzumab vs. THP as first-line treatment for HER2-positive unresectable, locally advanced or metastatic breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Trastuzumab — IV infusion
  • Drug: IBI354 — IV infusion
  • Drug: Docetaxel — IV infusion
  • Drug: Pertuzumab — IV infusion
  • Drug: Paclitaxel — IV infusion

Primary Outcomes

  • Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment (Until progression or death, up to 54 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-02-10
Completion: 2030-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 540 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Contact Information
Study Contact:
Xiaodong Sun
0512-69566088-8095
xiaodong.sun@innoventbio.com
Binghe Xu
8613501028690
xubinghe@medmail.com.cn
Chinese Academy of Medical Sciences and Peking Union Medical College
Interventions
  • Drug: Trastuzumab — IV infusion
  • Drug: IBI354 — IV infusion
  • Drug: Docetaxel — IV infusion
  • Drug: Pertuzumab — IV infusion
  • Drug: Paclitaxel — IV infusion
Study Locations (1 sites)
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing Municipality 100021 China
Eligibility Criteria
Participants are eligible to be included in the study only if they meet all of the following criteria: 1. Have signed the informed consent form (ICF) and are able to comply with the follow-up visits and related procedures required in the protocol. 2. Male or female participants: ≥18 years of age 3. Pathologically confirmed breast cancer: 1. Unresectable, locally advanced or metastatic breast cancer, i.e. participants who cannot be treated with curative intent and confirmed HER2-positive (HER2 IHC 3+ or HER2 ISH+) on specimens taken after confirmed locally advanced or metastatic disease by central testing. 2. Documented history of hormone receptor (HR)-positive (defined as estrogen receptor \[ER\] and/or progesterone receptor \[PgR\] positive \[ER or PgR ≥1%\]) or HR-negative after local testing in the metastatic setting according to ASCO/CAP guidelines. If a participant has more than one ER/PgR result after metastatic disease, the most recent result will be used. 4. No prior chemotherapy or HER2-targeted therapy for unresectable, locally advanced or metastatic breast cancer (first-line endocrine therapy is allowed for patients with metastatic breast cancer). Participants who have received chemotherapy or HER2-directed therapy in the neoadjuvant or adjuvant therapies and have a DFI of \>6 months from completion of systemic chemotherapy or HER2-targeted therapy to advanced or metastatic diagnosis are eligible. 5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1. 6. Evidence of radiographic or objective disease progression on or after the last systemic therapy prior to starting study treatment. 7. Have a life expectancy of ≥12 weeks at screening. 8. At least 1 measurable lesion as defined per RECIST v1.1 that has not been previously irradiated. Must be ≥ 10 mm in long axis (except for lymph nodes, which must be ≥ 15 mm in short axis) when accurately measured at baseline by CT or MRI (preferably with intravenous contrast) and the lesion is suitable for repeated accurate measurement. 9. Left ventricular ejection fraction (LVEF) ≥ 50% within 28 days prior to randomization. 10. Adequate organ and bone marrow function. Laboratory test values within 7 days prior to the first dose of the investigational product meet the following requirements in (if the laboratory tests during the screening period do not meet the following requirements, only one retest is allowed during the screening period): 1. Hemoglobin (HGB) ≥ 90 g/L (transfusion of red blood cells or erythropoietin are not allowed within 1 week prior to the screening assessment, and participants requiring ongoing transfusion or growth factor support to maintain hemoglobin ≥ 90 g/L are not eligible). 2. Absolute neutrophil count (ANC) ≥ 1.5 × 109 /L or within the normal range (G-CSF is not allowed within 1 week prior to the screening assessment). 3. Platelet (PLT) ≥ 90 × 109 /L (transfusion with platelets or thrombopoietin is not allowed within 1 week prior to screening assessment, participants requiring thrombopoietic growth factors to maintain adequate platelet count are not eligible). 4. Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN) in the absence of liver metastasis; TBIL \< 3 × ULN in the presence of Gilbert syndrome (unconjugated hyperbilirubinemia) or liver metastasis. 5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3×ULN (\<5×ULN for participants with liver metastases). 6. Serum albumin ≥ 25 g/L. 7. Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 60 mL/min ( calculated using the Cockcroft-Gault formula ); if urinalysis indicates that the urine protein is \< 2+, participants with urine protein ≥ 2+ from urinalysis at baseline should undergo a 24-hour urine collection and have a 24-hour urine protein quantitation \< 1 g (if both methods are used, a 24-hour urine protein quantitation will be used to determine participant eligibility). Cockcroft/Gault formula: Female: CrCl = (140 - Age) × Weight (kg) × 0.85 72 × serum creatinine (mg/dL) Male: CrCl = (140 - years) × weight (kg) × 1.00 72 × serum creatinine (mg/dL) 8. International normalized ratio (INR) ≤ 1.5 × ULN, and prothrombin time (PT) or activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. 11. Participants with evidence of postmenopausal status or negative serum pregnancy test (Sexually active, WOCBP with a non-sterilized male partner) must have a negative serum pregnancy test at the screening visit. WOCBP are women who are not surgically sterile (i.e., have undergone bilateral salpingectomy, bilateral oophorectomy, or total hysterectomy) or are not postmenopausal. 12. Female participants of childbearing potential or male participants with partners of childbearing potential must take effective contraceptive measures during the entire course of the trial and 6 months after the treatment Participants should not be included in the study if they meet any of the following criteria: 1. Prior treatment with antibody-drug conjugates containing camptothecin or its derivatives (topoisomerase I inhibitors). 2. Uncontrolled or significant cardiovascular and cerebrovascular diseases, including any of the following: 1. History of myocardial infarction or symptomatic congestive heart failure (New York Heart Association \[NYHA\] class II to IV) or uncontrolled myocarditis within 6 months before randomization. Participants with troponin levels above the ULN at screening (as specified by the manufacturer) and without any myocardial infarction-related symptoms should have a cardiology consultation before randomization to rule out myocardial infarction. 2. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg) despite of standard treatment. 3. History of any arterial thromboembolic events within 6 months prior to randomization, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack. 4. History of deep vein thrombosis, pulmonary embolism, or any other serious thromboembolic events within 3 months prior to randomization (thrombosis or catheter-derived thrombosis of caused by implanted venous ports, or superficial vein thrombosis, intermuscular vein thrombosis are not considered serious thromboembolisms). 5. History of arrhythmia (polymorphic premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia, ventricular fibrillation, torsades de pointes) that is symptomatic or requires treatment (CTCAE 5.0 Grade 3), atrial fibrillation that is symptomatic or uncontrolled despite treatment, or asymptomatic sustained ventricular tachycardia. Participants whose atrial fibrillation is controlled by medication or whose arrhythmia is controlled by a pacemaker will be allowed to be enrolled in the study. 6. Fridericia-corrected QT interval (QTcF) \>480 msec. If QTcF is \> 480 ms in 1 ECG during the screening period, 3 consecutive ECGs should be performed and the mean QTcF should be calculated. If QTcF is still \> 480 ms, the participant will not be enrolled. 7. History of QT prolongation associated with other drugs that require discontinuation, or any current concomitant medication known to prolong QT interval leading to Torsade de Pointes. 8. Congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death in first-degree relatives under 40 years old. 3. Non-infectious pneumonitis that requires corticosteroid treatment, or other clinically significant lung diseases such as a history of interstitial lung disease (ILD)/non-infectious pneumonitis, current ILD/non-infectious pneumonitis, or uncontrolled lung diseases (e.g., pulmonary fibrosis, severe radiation pneumonitis, and acute lung injury) or suspected ILD/non-infectious pneumonitis cannot be ruled out by imaging at screening. 4. Have a lung-specific intercurrent clinically significant illness including, but not limited to, any u
Conditions Breast Cancer, Ovarian Cancer, Cervical ...
Phase NA
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The investigators propose to: 1) Adapt an evidence-based cancer-focused patient navigation (PN) program for the Adolescent and Young Adult (AYA) cancer survivor population; and 2) Plan and conduct an effectiveness-implementation trial of this program within Kaiser Permanente Southern California (KPSC). PLEASE NOTE: This study is awarded in two phases. The UG3 phase has been awarded for the first two years; upon successful completion of this phase by meeting pre-defined milestones, the National Cancer Institute (NCI) will provide funding for the second phase of the study (Years 3-6), which will allow our team to conduct a trial to determine the effectiveness of the implementation of the adapted PN program for the AYA cancer survivor population. This application is focused on the initial UG3 phase and will update the protocol for the UH3 trial upon successful completion of the UG3 milestones and receipt of the UH3 award. The primary objectives in the UG3 phase of the study are to adapt and tailor an existing PN program to meet the needs of AYA cancer survivors and the local clinical context via (a) interviews with key stakeholders (patients, clinicians, administrators) and (b) guidance from our AYA Primary Care Survivorship Council. The investigators will conduct a pilot study of the adapted PN program and refine the program to enhance acceptability to patients and clinicians, enhance feasibility and effectiveness, and develop and pilot evaluation tools and methods prior to the start of the UH3 phase of the trial, which will be a larger trial. Objectives will be updated for the UH3 phase once awarded.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Adapted patient navigation program targeting adolescent and young adult cancer survivors — In the UG3 phase, the investigators will be adapting a patient navigation intervention to suit adolescent and young adult cancer survivors and conducting a single-site pilot test of the adapted intervention. The investigators will conduct a pilot test of the adapted AYA PN program at a single participating site, focusing on the perceptual implementation outcomes of acceptability, appropriateness, and feasibility and the hypothesized patient navigation program outcomes of increased motivation, capability, and opportunity for care. The pilot will also include testing of the patient identification algorithm, patient enrollment/engagement methods, clinical workflow, survey recruitment methods, and health IT elements (e.g., access, ease of use).

Primary Outcomes

  • Perceived Health Competence Scale (From enrollment to completion at 6 months post-enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-15
Completion: 2027-08
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kaiser Permanente
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Erin E Hahn, PhD (PRINCIPAL_INVESTIGATOR) - Kaiser Permanente Southern California, Department of Research & Evaluation
Contact Information
Study Contact:
Erin E Hahn, PhD
626-564-3505
Erin.E.Hahn@kp.org
Corrine E. Munoz-Plaza, MPH
626-564-3094
Corrine.E.Munoz-Plaza@kp.org
Interventions
  • Behavioral: Adapted patient navigation program targeting adolescent and young adult cancer survivors — In the UG3 phase, the investigators will be adapting a patient navigation intervention to suit adolescent and young adult cancer survivors and conducting a single-site pilot test of the adapted intervention. The investigators will conduct a pilot test of the adapted AYA PN program at a single participating site, focusing on the perceptual implementation outcomes of acceptability, appropriateness, and feasibility and the hypothesized patient navigation program outcomes of increased motivation, capability, and opportunity for care. The pilot will also include testing of the patient identification algorithm, patient enrollment/engagement methods, clinical workflow, survey recruitment methods, and health IT elements (e.g., access, ease of use).
Study Locations (1 sites)
KP Southern California - Department of Research & Evaluation, Pasadena, California 91101 United States
Eligibility Criteria
Inclusion Criteria: * Received diagnosis of local or regional breast, ovarian, cervical, testicular, colon/rectal, melanoma, endometrial, sarcoma, or thyroid cancer between the ages of 15-39 years ("index cancer") * Current age 21-45 years * Diagnosed and treated for index cancer within Kaiser Permanente Southern California adult medical oncology and/or surgery * Current Kaiser Permanente insurance coverage Exclusion Criteria: * Patients with a history of or current diagnosis of leukemia or lymphoma * Patients with metastatic disease at diagnosis
Conditions Type 2 Diabetes
Phase NA
Enrollment 104
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to investigate how fat accumulation in the pancreas contributes to the development of type 2 diabetes (T2D), and how weight loss may reverse this process. Previous research has shown that reducing body weight can lead to diabetes remission, and this was accompanied by lowering intrapancreatic fat and restoration of insulin secretion, but the mechanisms behind this are not fully understood. In particular, the study aims to unravel the role of hepatic de novo lipogenesis (DNL) and lipoprotein metabolism on pancreas lipotoxicity and beta cell recovery after weight loss. Four groups of participants will be recruited (n=26 per group): non-diabetic, pre-diabetic, short-duration T2D (\<6 years), and long-duration T2D (\>10 years). Participants will be aged between 45 and 79 years and have a BMI between 30 and 45 kg/m². All participants will follow a structured weight loss programme using an 800 kcal/day Total Diet Replacement (TDR) for 8-12 weeks, followed by dietary support to maintain weight loss. The study is sponsored by NHS-Lothian and the University of Edinburgh and will be carried out at the Clinical Research Facility, Royal infirmary of Edinburgh by a specialist team (Senior Diabetes Research Nurse, Clinical Fellow, and Research Dietitian). The primary endpoint of this study is to achieve a 10-15% reduction in body weight (\~10 kg) through a low-calorie diet (800 kcal/day) to induce T2D remission and maintain this weight loss with structured dietary support for up to 6-12 months. The primary aim is to compare hepatic de novo lipogenesis-the conversion of sugar into fat by the liver-and lipoprotein export among the groups, and to examine how these parameters change in response to weight loss, improvement in metabolic status, and restoration of normal pancreatic function. Secondary endpoints include changes in weight, HbA1c, intraorgan fat (liver/pancreas), pancreas volume and tissue characteristics, beta cell mass and function (MRI/mixed meal test), circulating blood markers (i.e. lipids, exosomes, adipokines, and inflammatory markers), and the change in adipose tissue biology (fat biopsies). Ultimately, this study aims to understand the mechanisms of T2D remission. It will help clarify the sequence of metabolic events leading to reversible pancreatic lipotoxicity and may inform the development of new, targeted therapies for T2D.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Total Diet Replacement (TDR) Program — Participants will follow a structured Total Diet Replacement (TDR) program consisting of approximately 800 kcal/day using commercially available soups and shakes for 8-12 weeks. This is followed by a 2-week food reintroduction phase and a weight maintenance phase up to 6 months, supervised by a research dietitian. The intervention aims to induce rapid weight loss and assess its impact on intrapancreatic fat, insulin secretion, and type 2 diabetes remission. All participants receive dietary counseling and monitoring throughout the study.

Primary Outcomes

  • Change in body weight from baseline to 6-12 months post-intervention (Baseline, 6 months, and 12 months post-intervention)
  • Change in hepatic de novo lipogenesis measured using stable isotope tracers (Baseline, 6 months, and 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-15
Completion: 2029-12-31
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: true
Enrollment: 104 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Edinburgh
Collaborators: NHS Lothian
Principal Investigators:
  • Ahmad Al-Mrabeh, PhD (PRINCIPAL_INVESTIGATOR) - University of Edinburgh
Contact Information
Study Contact:
Study Team
+44(0)131 242 6717
edrs@ed.ac.uk
Study Team
+44 131 242 6717
edrs@ed.ac.uk
Clinical Research Facility, Royal Infirmary of Edinburgh
Interventions
  • Behavioral: Total Diet Replacement (TDR) Program — Participants will follow a structured Total Diet Replacement (TDR) program consisting of approximately 800 kcal/day using commercially available soups and shakes for 8-12 weeks. This is followed by a 2-week food reintroduction phase and a weight maintenance phase up to 6 months, supervised by a research dietitian. The intervention aims to induce rapid weight loss and assess its impact on intrapancreatic fat, insulin secretion, and type 2 diabetes remission. All participants receive dietary counseling and monitoring throughout the study.
Study Locations (1 sites)
Clinical Research Facility, Royal Infirmary of Edinburgh, Edinburgh, EH16 4SA United Kingdom
Eligibility Criteria
Inclusion Criteria: * Overweight/obese (BMI: 30-45 kg/m²) who have had T2D for less than 6 years or longer than 10 years, and are on treatment with diet alone or diet plus oral medication. * Overweight/obese (BMI: 30-45 kg/m²) who are at pre-diabetes stage, defined as fasting blood glucose 5.6-6.9 mmol/L. * Overweight/obese (BMI: 30-45 kg/m²) who are non-diabetic (control group). * Age between 45 and 79 years inclusive. * Post-menopausal women only (to exclude sex hormone effects on lipid metabolism). * Good communication in English (able to give informed consent and follow dietary advice). * Willing and able to adhere to the study protocol, including dietary intervention and scheduled follow-up visits. Exclusion Criteria: * Insulin therapy * HbA1c \>12% (108 mmol/mol) * Weight loss \>5 kg in last 6 months * Recent MI (within 6 months) * Known cancer in last 5 years * First-degree relatives of people with T2D (control group) * History of gestational diabetes * MRI contraindications (metal implants, claustrophobia) * Alcohol \>14 units/week * Advanced kidney or liver disease * Use of steroids or antipsychotics * Participation in another clinical trial * Life expectancy \<1 year * Allergy to local anaesthetic (for biopsy subgroup) * Any disorder that may jeopardise safety or compliance
Conditions Qualitative Research
Phase Not Applicable
Enrollment 15
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to investigate asthma patients' experiences with an 8 week IMT and the perceived effects of this intervention on physical activity, coping strategies, and asthma self-management. A qualitative methodological design will be applied to understand the experiences of patients participating in the IMT program, how the program affected their daily activities, how they coped with symptoms and difficulties, and how they managed their condition.

Design

Study type: Observational Observational model: Other Time perspective: Other

Interventions / Regimen

  • Other: other — Other: Telephone concept elicitation interview All interview questions are designed to be quite open-ended in order to determine participants' preferences in an unbiased manner (as much as possible). Additional questions will only be used when necessary to ensure that all relevant concepts are covered. Participants will be asked questions about the effects of inspirational muscle training they have previously experienced on their daily lives, coping strategies, and self-management processes.

Primary Outcomes

  • Patient-reported experiences of inspiratory muscle training (IMT) assessed by semi-structured in-depth interviews (study-specific interview guide) (Single assessment after completion of the 8-week IMT program (within 4 weeks after IMT completion))
  • Experience of exercising using telerehabilitation assessed by semi-structured in-depth interviews (study-specific interview guide) (Single assessment after completion of the 8-week IMT program (within 4 weeks after IMT completion))
  • Changes in physical activity in daily life assessed by semi-structured in-depth interviews (study-specific interview guide) (Single assessment after completion of the 8-week IMT program (within 4 weeks after IMT completion))
  • Self-management skills assessed by semi-structured in-depth interviews (study-specific interview guide) (Single assessment after completion of the 8-week IMT program (within 4 weeks after IMT completion))
  • Coping strategies assessed by semi-structured in-depth interviews (study-specific interview guide) (Single assessment after completion of the 8-week IMT program (within 4 weeks after IMT completion))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-05
Completion: 2027-12-19
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istanbul Esenyurt University
Contact Information
Study Contact:
Esra PEHLİVAN, PhD
+90 216 777 96 00
fztesrakambur@yahoo.com
Cahidenur Koçak
05511812675
cahidekocak25@gmail.com
Istanbul Esenyurt University
Interventions
  • Other: other — Other: Telephone concept elicitation interview All interview questions are designed to be quite open-ended in order to determine participants' preferences in an unbiased manner (as much as possible). Additional questions will only be used when necessary to ensure that all relevant concepts are covered. Participants will be asked questions about the effects of inspirational muscle training they have previously experienced on their daily lives, coping strategies, and self-management processes.
Study Locations (1 sites)
Istanbul Esenyurt University, Istanbul, Istanbul 34890 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Being between the ages of 18-65 * Having been diagnosed with severe persistent, non-allergic asthma by a pulmonologist in accordance with the Global Initiative for Asthma (GINA) guideline criteria, * Patients with type 2 inflammation markers. According to accepted standards; peripheral eosinophils \<150/µL and/or negative skin prick test and/or total IgE \<30 kU/L * Bronchodilator response (\>12% or 200 mL improvement in FEV1% predicted following inhalation of 400 mg salbutamol) * Diagnosis-follow-up period: Patients diagnosed at least 6 months prior, under follow-up and treatment, and/or with controlled asthma * Having completed the pulmonary rehabilitation program * Completion of 8 weeks of inspiratory muscle training (IMT) * Patients who have read, understood, and signed the informed consent form Exclusion Criteria: * Having recently had a respiratory tract infection recently (within the last month), * Having a smoking history of more than 10 pack-years or having a history of smoking within 6 months after quitting smoking * Having received oral corticosteroid treatment in the last 4 weeks, * Having a Body Mass Index \>35, * Eosinophilic Granulomatosis Polyangiitis (EGPA) and Allergic Bronchopulmonary Aspergillosis (ABPA), * Vasculitis, * History of malignancy, * Pregnancy, * Previous lung surgery, use of long-term oxygen therapy * Having accompanying restrictive lung diseases (advanced kyphoscoliosis, ankylosing spondylitis) and neuromuscular diseases (myastania gravis, muscular dystrophies, myopathies) that will prevent healthy respiratory function testing and rehabilitation. * Cognitive dysfunction, mental retardation, dementia, or other conditions that make it difficult to follow the protocol, * Unwillingness to continue participating in the study, * Communication difficulties or intellectual deficiencies
Conditions Critical Illness Recovery, Behavioral He...
Phase NA
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This pilot study evaluates the feasibility and acceptability of implementing a Behavioral Health Collaborative Care Model (BH CoCM) for family members of ICU survivors. The intervention includes telehealth-enabled behavioral health assessments and access to the NeuroFlow platform. A subset of participants will undergo qualitative interviews.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Behavioral Treatment — behavioral health collaborative care model in ICU recovery patients and families

Primary Outcomes

  • Consent Rate (Baseline)
  • Study Completion Rate (enrollment to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-30
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of South Carolina
Collaborators: Health Resources and Services Administration (HRSA)
Principal Investigators:
  • Rita Bakhru, MD (PRINCIPAL_INVESTIGATOR) - Medical University of South Carolina
Contact Information
Study Contact:
Rita Bakhru, MD
8437920965
recruitment@musc.edu
Rita Bakhru, MD
bakhru@musc.edu
Medical University of South Carolina
Interventions
  • Behavioral: Behavioral Treatment — behavioral health collaborative care model in ICU recovery patients and families
Study Locations (1 sites)
Medical University of South Carolina, Charleston, South Carolina 29407 United States
Eligibility Criteria
Inclusion Criteria: \- Family member of ICU Recovery Clinic patient enrolled in parent BH CoCM study Exclusion Criteria: * Serious mental illness (e.g., schizophrenia, mania) * Late-stage dementia or cognitive impairment * Limited English proficiency * No internet-enabled device * Prisoners
Conditions Breast Cancer
Phase Not Applicable
Enrollment 750
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to learn more about risks and outcomes of breast cancer in people with different backgrounds. Tissue and blood will be collected from participants for research purposes. Participants will complete questionnaires during their standard medical care. The study will not provide treatment for cancer or any other condition.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Survey — Complete surveys: * Baseline (within 6 months of enrollment) * 1st follow-up survey (approx. 6 months to 12 months) * 2nd follow-up survey and/or blood collection (approx. 3 years +/- 6 months) * 3rd follow-up survey and/or blood collection (approx. 5 years +/- 6 months)

Primary Outcomes

  • Recurrence Free Survival/RFS (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-08
Completion: 2031-12-08
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 750 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • Neha Goel, MD, MPH (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Neha Goel, MD, MPH
646-888-4298
goeln1@mskcc.org
George Plitas, MD
646-888-5368
PlitasG@mskcc.org
Neha Goel, MD, MPH
646-888-4298
Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities)
Interventions
  • Other: Survey — Complete surveys: * Baseline (within 6 months of enrollment) * 1st follow-up survey (approx. 6 months to 12 months) * 2nd follow-up survey and/or blood collection (approx. 3 years +/- 6 months) * 3rd follow-up survey and/or blood collection (approx. 5 years +/- 6 months)
Study Locations (7 sites)
Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey 07920 United States
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey 07748 United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack, New York 11725 United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York 10604 United States
Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York, New York 10065 United States
Memorial Sloan Kettering Nassau (Limited Protocol Activites), Rockville Centre, New York 11553 United States
Eligibility Criteria
Women 18 years and older who are patients with a suspicious breast finding who present to breast radiology at MSK for biopsy or any new breast cancer patient seen at MSK undergoing surgery. Inclusion Criteria: A patient cannot be considered eligible for this study unless the following conditions are met. * Patients with a suspicious breast finding who present to breast radiology at MSK for biopsy or any new breast cancer patient who is a surgical candidate seen at MSK. * Women 18 years of age and older are eligible to participate in the study. Exclusion Criteria: * Patients presenting with a suspicious breast mass or breast cancer less than 1 cm. * Patients presenting to clinic with only microinvasion * Patients who are less than 18 years of age * Patients unable to complete the survey, including IDMC patients.
Conditions Glaucoma
Phase NA
Enrollment 120
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to understand how light sensitivity in the eye affects sleep, mood, alertness, and cognition in adults with glaucoma compared to healthy individuals aged 45-75 years. The main questions it aims to answer are: 1. Do patients with glaucoma experience poorer sleep, mood, alertness, and cognitive function than age-matched healthy adults? 2. Are these changes related to reduced light sensitivity in special retinal cells called intrinsically photosensitive retinal ganglion cells (ipRGCs), lost in glaucoma? 3. Can exposure to safe, full-spectrum indoor light help improve these functions? Researchers will compare patients with glaucoma and age-matched healthy controls to see if differences in light sensitivity can explain changes in non-visual light responses (i.e., sleep, mood, alertness, and cognition) and whether full-spectrum light exposure can enhance alertness and wellbeing. Participants will: 1. Complete eye exams and baseline questionnaires about their sleep, daytime sleepiness, mood, and wellbeing. 2. Wear a wrist-worn device for 8-16 days to record their sleep patterns and light exposure. 3. Visit the laboratory for cognitive and attention tests following exposure to two lighting conditions (randomized, cross-over): * Standard indoor light (\~300 lux) * Full-spectrum light (\~1000 lux) This study will help researchers understand how glaucoma affects the brain beyond vision and explore whether light-based interventions can improve quality of life for people living with glaucoma.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Full-spectrum light exposure — Participants will be exposed to a full-spectrum white light designed to replicate the spectral quality of natural daylight while maintaining safe, indoor intensity levels. The light source delivers an illuminance of approximately 1000 lux and is free of ultraviolet and infrared wavelengths. Each participant will undergo two periods of light exposure, intermittently, during the laboratory visit at the Eye N' Brain Research Platform (NUS).
  • Other: Standard indoor light exposure (Control) — Participants will be exposed to a standard indoor light with an illuminance of approximately 300 lux. Each participant will undergo two periods of light exposure, intermittently, during the laboratory visit at the Eye N' Brain Research Platform (NUS).

Primary Outcomes

  • Subjective Sleep Quality (Baseline (Visit 1))
  • Subjective Daytime Sleepiness (Baseline (Visit 1))
  • Depressive Symptoms (Baseline (Visit 1))
  • Global Cognitive Function (Baseline (Visit 1))
  • Global Cognitive Function during light exposure (Immediately after the procedure)
  • Median Reaction Time (Immediately after the procedure)
  • Vigilance Lapses (Immediately after the procedure)
  • Long Reation Time Lapses (Immediately after the procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-05
Completion: 2026-12
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National University of Singapore
Collaborators: Singapore National Eye Centre, Singapore Eye Research Institute, National University Hospital, Singapore
Principal Investigators:
  • Raymond P. Najjar, PhD (PRINCIPAL_INVESTIGATOR) - National University of Singapore
Contact Information
Study Contact:
Daniella Mahfoud, MSc.
+65 65165474
daniella.mahfoud@u.nus.edu
Daniella Mahfoud, MSc.
+65 6516 5474
daniella.mahfoud@u.nus.edu
National University Hospital
Victor Koh, MD
National University Hospital
Interventions
  • Other: Full-spectrum light exposure — Participants will be exposed to a full-spectrum white light designed to replicate the spectral quality of natural daylight while maintaining safe, indoor intensity levels. The light source delivers an illuminance of approximately 1000 lux and is free of ultraviolet and infrared wavelengths. Each participant will undergo two periods of light exposure, intermittently, during the laboratory visit at the Eye N' Brain Research Platform (NUS).
  • Other: Standard indoor light exposure (Control) — Participants will be exposed to a standard indoor light with an illuminance of approximately 300 lux. Each participant will undergo two periods of light exposure, intermittently, during the laboratory visit at the Eye N' Brain Research Platform (NUS).
Study Locations (2 sites)
National University Hospital, Singapore, Singapore
Singapore National Eye Center, Singapore, Singapore
Eligibility Criteria
Inclusion Criteria: * Patients with glaucoma must meet all of the inclusion criteria to participate in this study. * Patients diagnosed with primary open-angle glaucoma (POAG), as indicated by Humphrey Visual Field (HVF) mean deviation (VFMD) scores better than -12 dB in at least one eye during their most recent clinic visit. * Patients having spared central vision. * Patients aged 45 to 75 years old. * Patients with a best-corrected visual acuity better than 6/12 * English-speaking patients Healthy controls must meet all of the inclusion criteria to participate in this study: * Participants aged 50 to 70 years old. * Participants with a best-corrected visual acuity better than 6/12 * Normal ophthalmic examination * English-speaking participants Exclusion Criteria: * All subjects (patients and controls) meeting any of the exclusion criteria at baseline will be excluded from participation: * Participants with myopia exhibiting a refractive error exceeding -8.00 diopters (D) * Participants with a history of complicated previous intraocular surgery * Participants taking alpha-adrenergic agonist eye drops or other systemic medications or drugs that could affect the pupillary response * Participants with any past or current ocular condition (i.e., age-related retinal diseases (e.g., age-related macular degeneration), retinal pigment epithelium diseases (e.g., Best's disease), diabetic retinopathy, or other optic or generalized neuropathies, significant ocular trauma, or any eye condition affecting fixation (eg. Nystagmus)). * Participants diagnosed with cataracts at NS3+ (Nuclear Sclerosis) and above, as well as those with Posterior Subcapsular (PSC) cataracts * Participants with clinically diagnosed psychiatric or neurologic disorders, including cognitive impairment or dementia * Participants with diagnosed mood disorders * Participants engaged in night shift work within the past three months, are currently using sleeping pills, or have recently travelled across timezones within a month prior to the study * Participants with obstructive sleep apnea * Participants with abnormal auditory function * Participants with impaired color vision * Pre-menopausal women (last menstrual period \< 1 year) (If applicable) * Patients having unilateral glaucoma, congenital glaucoma, non-glaucomatous optic neuropathy, abnormal central vision * Diabetics on treatment
Conditions Sleep Disturbance, Cognitive Change, Agi...
Phase Not Applicable
Enrollment 250
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This project aims to build up the comprehensive health database of geriatric medicine for middle-aged and elderly people in Taiwan.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Primary Outcomes

  • The brain volume of local Taiwanese aged over 40 years old (one hour)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-09-15
Completion: 2028-12-31
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: true
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chang Gung Memorial Hospital
Collaborators: Chang Gung University
Contact Information
Study Contact:
JI-TSENG FANG, Professor
+886-3-3281200
fangjits@cgmh.org.tw
JI-TSENG FANG, Professor
+886-3-3281200
fangjits@cgmh.org.tw
Taipei Chang Gung Memorial Hospital
JI-TSENG FANG, Professor
+886-3-3281200
fangjits@cgmh.org.tw
Taoyuan Chang Gung Memorial Hospital
Interventions
N/A
Study Locations (2 sites)
Taipei Chang Gung Memorial Hospital, Taipei, 105 Taiwan
Taoyuan Chang Gung Memorial Hospital, Taoyuan, 333 Taiwan
Eligibility Criteria
Inclusion Criteria: * Willing to sign a written participant consent form. * Males or females aged 40 or above who have participated in the "Integrated Systematic Geriatric Medical Information to Explore Solutions for Healthy Aging (Pilot Project)," the "Integrated Systematic Geriatric Medical Information to Explore Solutions for Healthy Aging" master planner, or the "Integrated Systematic Medical Information to Explore Solutions for Healthy Aging" project (not subject to exclusion criteria). * Males or females aged 40-59 who have participated in health checkups for employees of Chang Gung Memorial Hospital, Formosa Plastics Group, or Chang Gung University. * Those with a medical record of more than one year at Chang Gung Memorial Hospital. * Those who have resided in Taiwan for more than 180 days in the past year. Exclusion Criteria: * Individuals with severe organ abnormalities, such as: heart failure (NYHA Fc ≥ III), chronic obstructive pulmonary disease (hospitalization/emergency room visit or medication adjustment within the past month due to disease worsening), decompensated cirrhosis, hemodialysis, or currently undergoing cancer treatment. * Individuals with a history of severe autoimmune diseases. * Individuals with a preliminary cognitive and mental assessment score of \<26 on the Mini-Mental State Examination (MMSE) or ≥5 on the Generalized Depression Scale (GDS). * Individuals (who agree to undergo brain MRI) who are deemed unsuitable for MRI after evaluation (e.g., those with pacemakers, cochlear implants, or spatial phobia). * Individuals who have taken antibiotics within the past month. * Individuals whose hearing, vision, or cognitive impairments affect communication. * Individuals unable to stand or walk (with a walking aid) or with unsteady gait when walking. * Those who have undergone follow-up outpatient assessments that may affect cognitive function, including but not limited to stroke, Parkinson's syndrome, Parkinson's dementia, epilepsy, brain tumor, or a history of mental illness such as schizophrenia, severe depression, bipolar disorder, alcohol or drug abuse, or a history of loss of consciousness due to severe head trauma. * Those currently diagnosed with depression and undergoing treatment. * Those with a past medical history confirming dementia, depression, etc.. * Those deemed unsuitable by a physician.
Conditions Depressive Disorder, Anxiety, Adolescent
Phase NA
Enrollment 40
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the feasibility of a structured breathing intervention in rural and non-rural adolescents diagnosed with anxiety and depression, recruited from outpatient pediatric and child/adolescent psychiatry clinics.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Behavioral: Breathing Intervention — Participants will follow a structured breathing practice (Seokmun Hoheup) that progresses in incremental steps, beginning with 15 minutes, increasing to 30 minutes, and then to 36 minutes per session over the course of the program.

Primary Outcomes

  • Feasibility of Intervention Measure (FIM) score (4 months)
  • Acceptability of Intervention Measure (AIM) score (4 months)
  • Intervention Appropriateness Measure (IAM) score (4 months)
  • Recruitment feasibility (4 months)
  • Retention feasibility (4 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-19
Completion: 2027-01
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Pravesh Sharma (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Danielle Boos
715-464-8173
boos.danielle@mayo.edu
Marin Nycklemoe
507-255-2814
nycklemoe.marin@mayo.edu
Marin Nycklemoe
507-255-2814
Mayo Clinic Health System-Albert Lea
Interventions
  • Behavioral: Breathing Intervention — Participants will follow a structured breathing practice (Seokmun Hoheup) that progresses in incremental steps, beginning with 15 minutes, increasing to 30 minutes, and then to 36 minutes per session over the course of the program.
Study Locations (2 sites)
Mayo Clinic Health System-Albert Lea, Albert Lea, Minnesota 56007 United States
Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin 54703 United States
Eligibility Criteria
Inclusion Criteria: * Adolescents between the ages of 12 and 17 who have been diagnosed with a major depressive disorder (mild or moderate) and/or an anxiety disorder. * Participants may have co-occurring mild to moderate alcohol or drug use problems, provided these do not require immediate specialized treatment or crisis intervention. * All participants must be receiving care at one of two participating MCHS outpatient psychiatry clinics and may reside in rural area (RUCA code 4-10) or non-rural area. * Participants must be able to read and understand English, and both parental or guardian consent and adolescent assent will be required. Exclusion Criteria: * Current suicidal ideation or self-harm behavior requiring immediate clinical intervention * Presence of severe psychiatric comorbidities such as psychosis, bipolar disorder, depression with psychotic features, severe alcohol and drug use, or eating disorders. * Participants with significant cognitive impairment that would interfere with study participation.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 245
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A single-center, real-world study evaluated the clinical outcomes and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2- advanced breast cancer, and conducted a summary analysis of the clinical treatment options after the progression of CDK4/6 inhibitors.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Primary Outcomes

  • rwPFS1 and rwPFS2 (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-06-01
Completion: 2027-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 245 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital
Contact Information
Study Contact:
Yehui Shi, MD
022-23340123-3252
shiyehui@tjmuch.com
Yiran Si, MD
022-23340123-3252
Yehui Shi, MD
022-23340124-3252
shiyehui@tjmuch.com
Tianjin Medical University Cancer Insititute and Hospital
Interventions
N/A
Study Locations (1 sites)
Tianjin Medical University Cancer Insititute and Hospital, Tianjin, 300060 China
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years old; 2. Patients diagnosed with HR+/HER2- (as defined by the ASCO/CAP guidelines) advanced breast cancer who were treated in our hospital from March 2022 to March 2025; 3. Received CDK4/6 inhibitors (including but not limited to the four currently marketed ones: palbociclib, abemaciclib, ribociclib, and dalpiciclib) as advanced-stage treatment for at least one cycle; 4. Have complete medical history records, including demographic information, pathological reports, treatment records, laboratory test results, and imaging examination reports, etc. Exclusion Criteria: 1. Incomplete medical history data. 2. Only received CDK4/6 inhibitors monotherapy. 3. Received CDK4/6 inhibitors as neoadjuvant/postoperative adjuvant intensification therapy.